Glenmark gets USFDA nod for Theophylline ER tablets

Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets USP, 450 mg

43
USFDA
Picture: Pixabay

Glenmark Pharmaceuticals Limited (Glenmark) has received final approval from the United States Food & Drug Administration (USFDA) for theophylline extended release tablets, 300 mg and 450 mg, bioequivalent and therapeutically equivalent to the reference listed drug, theophylline extended release tablets, 300 mg and 450 mg, of Alembic Pharmaceuticals Limited.

Medicine
Picture: Pixabay

Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets USP, 450 mg, therefore, with this approval, Glenmark is the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing of the 450 mg strength.

According to IQVIA sales data for the 12 month period ending April 2021, the theophylline extended release tablets, 300 mg and 450 mg market achieved annual sales of approximately $47.8 million.

Glenmark’s current portfolio consists of 173 products authorized for distribution in the US market place and 44 ANDA’s pending approval with the USFDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Zydus Cadila gets tentative USFDA nod for Osimertinib Tablets

Zydus Cadila gets USFDA nod for Fluphenazine HCL Tablets

Glenmark gets USFDA nod for Icatibant injection single-dose prefilled syringe

NATCO Pharma gets USFDA nod for Everolimus tablets

Natco Pharma gets USFDA nod for Lenalidomide capsules

Unichem Labs gets USFDA approval for Amitriptyline HCL Tablets

ICMR approved Self-test kit for C-19 launched

Serum Institute seeks DCGI’s nod to manufacture Sputnik V vaccine

Black fungus drug: Black marketing Racket busted

Zydus Cadila gets tentative USFDA nod for Osimertinib Tablets

Sun Pharma, Ferring Pharma sign agreement to launch CARITEC in India

USFDA accepts application from Lupin for Pegfilgrastim Biosimilar

Subscribe for daily free updates on Telegram

Follow us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Enter your email address:

Delivered by FeedBurner